The Influence of Oxytocin on the Blood Perfusion of Uterine Fibroids: Contrast-enhanced Ultrasonography Evaluation  by Wang, Yang et al.
Journal of Medical Ultrasound (2016) 24, 13e17Chinese Taipei Society of
Ultrasound in Medicine 
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.jmu-onl ine.comORIGINAL ARTICLEThe Influence of Oxytocin on the Blood
Perfusion of Uterine Fibroids: Contrast-
enhanced Ultrasonography Evaluation
Yang Wang, Dehong Ren, Wei Wang*Department of Ultrasound, Chinese PLA General Hospital, Beijing, ChinaReceived 6 August 2015; accepted 10 November 2015
Available online 3 February 2016KEYWORDS
contrast-enhanced
ultrasongraphy,
oxytocin,
uterine fibroidConflicts of interest: The authors h
* Correspondence to: Dr Wei Wang,
E-mail address: wangyang301haina
http://dx.doi.org/10.1016/j.jmu.2015
0929-6441/ª 2016, Elsevier Taiwan LL
BY-NC-ND license (http://creativecomAbstract Background: High intensity focused ultrasound ablation is a new technique for the
treatment of uterine fibroids. Its efficacy is influenced by the blood perfusion of the fibroids.
Oxytocin is a promising drug which may decrease the blood flow to the fibroids. In this study,
the alterations of blood flow to the uterine fibroids were observed using contrast-enhanced so-
nography (CEUS) before and after the use of parenteral oxytocin.
Methods: A total of 40 women with 42 fibroids (mean  standard deviation, 5.8  1.9 cm;
range, 3.1e12.9 cm) underwent CEUS before and after intravenous infusion of oxytocin at
0.1 U/min. The CEUS time-intensity curves were drawn, the maximum signal intensity, the
time-to-peak intensity and mean transit time of the fibroids were measured to observe the
changes of perfusion after the use of oxytocin.
Results: After the use of oxytocin, the wash-in of microbubbles was significantly slowed down
on CEUS in all patients. The maximum signal intensity of the fibroids decreased significantly
and the time-to-peak intensity and mean transit time of the fibroids were prolonged signifi-
cantly after the use of oxytocin in all patients (p < 0.05). The results suggested that the blood
flow in the uterine fibroids was significantly decreased by the use of parenteral oxytocin.
Conclusion: This CEUS study demonstrated that the use of parenteral oxytocin can significantly
reduce the blood perfusion of the uterine fibroids, which may help to enhance the therapeutic
efficacy for high intensity focused ultrasound ablation of uterine fibroids.
ª 2016, Elsevier Taiwan LLC and the Chinese Taipei Society of Ultrasound in Medicine. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Figure 1 The region-of-interests (ROIs) are drawn in the
maximum cross-sectional area of the fibroid. Using the gray-
scale sonogram on the right as a reference, the ROI of the
fibroid (green area) is manually set w2 mm away from the
border of the fibroid on the contrast-enhanced sonography
sonogram. The ROI of the uterine wall (yellow area) is drawn in
the same sonogram.
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Uterine fibroids are the most common benign tumors in the
female genital tract [1]. About 25% of them are symptom-
atic which may cause menorrhagia, pelvic pain, and infer-
tility [2]. Hysterectomy or myomectomy was the traditional
treatment for symptomatic uterine fibroids. However, in
the past decade, many minimally-invasive techniques have
been developed for the treatment of fibroids and preser-
vation of the uterus [3e10].
High intensity focused ultrasound (HIFU) ablation is a
promising technique for the treatment of uterine fibroids.
Under imaging guidance, coagulative necrosis can be
induced in fibroids without damaging the overlying tissue.
As treatment is repeatable and can be performed on an
outpatient basis, HIFU ablation has become popular
recently [8e10]. One essential factor influencing the effi-
cacy of HIFU ablation is the perfusion mediated “heat-sink”
which hampers heat deposition inside the fibroid, resulting
in prolonged therapeutic time, decreased ablation volume,
and irregular coagulative area [11,12]. Decreasing the
blood flow to the fibroids may increase heat deposition,
thereby increasing the therapeutic outcome and reducing
the treatment time.
A previous study demonstrated that most fibroids had a
peripheral distribution of vascular supply [13]. Methods
which can induce contraction of the uterine smooth mus-
cles may compress the peripheral vessels, reducing the
blood flow to the fibroids. Oxytocin is a peptide hormone
with receptors in both pregnant and nonpregnant uterus
[14]. Because it can stimulate the smooth muscles of the
uterus to contract, oxytocin has been used to augment
labor or control postpartum hemorrhage [15,16]. We hy-
pothesize that oxytocin may also be used to decrease the
blood flow to the fibroids in a nonpregnant uterus, thereby
augmenting the efficacy of HIFU ablation.
Contrast-enhanced ultrasonography (CEUS) is a new im-
aging technique which can depict the blood flow of the
tumor in real-time, allowing for quantitative evaluation of
blood perfusion parameters [17]. The purpose of this study
was to use CEUS as a tool to investigate whether parenteral
oxytocin can decrease the blood perfusion of the uterine
fibroids.
Materials and Methods
Patients
From January 2013 to December 2014, 40 premenopausal
women with 42 symptomatic uterine fibroids underwent
CEUS examinations before receiving US-guided HIFU abla-
tion in our department. The inclusion criteria were as fol-
lows: (1) the largest diameter of the fibroid  3 cm; (2) the
number of the fibroids  3; (3) an acoustic pathway for
HIFU ablation was present; and (4) fibroids received no
treatment before HIFU ablation. The exclusion criteria
were as follows: (1) pregnancy; (2) allergy to CEUS agent;
and (3) contraindications to the use of oxytocin. This study
was approved by the Institutional Review Committee (Chi-
nese PLA General Hospital, Beijing, China) and informed
consent was obtained in all patients at enrollment.The age of the patients ranged from 29 years to 49 years
(mean, 40.0  6.0 years). Thirty-eight patients had a single
fibroid and two patients had two fibroids. The maximum
diameter of the fibroid ranged from 3.1 cm to 12.9 cm
(mean, 5.8  1.9 cm). Twenty-three fibroids were located
intramurally, 13 fibroids were located submucosally, and six
fibroids were located subserosally.
CEUS procedures
A Sequoia 512 US system (Acuson, Mountain View, CA, USA)
equipped with contrast pulse sequencing software was used
for CEUS. The contrast agent was SonoVue (Bracco, Milan,
Italy), which was supplied as a lyophilized power and
reconstituted with 5 mL of saline to form a homogeneous
microbubble suspension that contains sulphur hexafluoride
stabilized by a phospholipid shell. An ultrasound scan was
performed with a 4V1 transducer (1e4 MHz), CEUS was
performed at a mechanical index of 0.16e0.18. For all CEUS
procedures, a bolus injection of a 1.0 mL SonoVue was
administered via the cubital vein which was followed by a
5 mL saline flush, and the fibroids were observed continu-
ously for at least 4 minutes. Baseline CEUS was performed
first without the administration of oxytocin. Then, oxytocin
(Hefeng Pharmaceuticals, Shanghai, China) was adminis-
tered at a rate of 0.1 U/min with a microinjection pump via
the cubital vein, and the second CEUS was performed
15 minutes later. The dose of oxytocin was chosen after
consultation of experienced surgeons and pharmacologists.
CEUS was performed by one of three physicians (Y.W.,
D.H.R., and W.W.), each with more than 5 years’ experi-
ence in CEUS. The videos were recorded digitally on a hard
disc for off-line analysis. During CEUS examinations, the
heart rate, blood pressure, and oxygen saturation of the
patients were continuously monitored.
Analysis of CEUS was performed using a trial version of
sonoliver software (TomTec Imaging Systems, Munich,
Germany). The region-of-interests (ROIs) were drawn in the
maximum crosssectional area of the fibroid. Using the
Figure 2 The contrast-enhanced sonography changes of blood perfusion of the fibroid before and after intravenous adminis-
tration of oxytocin at 0.1 U/min. (A) Before the use of oxytocin, the fibroid began to enhance 18 seconds after bolus injection of
SonoVue. The green area corresponds to the location of the fibroid. The border of the uterine wall is marked by arrows. (B) The
fibroid reached maximum signal intensity 20 seconds after bolus injection of SonoVue. (C) Sixty seconds after bolus injection of
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Table 1 The changes of contrast-enhanced sonography blood perfusion parameters in patients with symptomatic uterine
fibroids.
Fibroidsa Uterine walla
Imax (%) TTP (s) MTT (s) Imax (%) TTP (s) MTT (s)
Before the use of oxytocin 102.7  59.5 15.9  4.8 73.9  35.0 100 17.9  7.4 103.9  72.2
After the use of oxytocin 15.5  16.9 28.3  14.0 119.4  109.2 100 15.8  5.5 105.8  89.3
p < 0.001 < 0.001 0.02 0.17 0.89
Imax Z the maximum intensity; MTT Z the mean transit time; TTP Z the time to peak intensity.
a The uterine wall was defined as the reference area. The Imax of the uterine wall was 100% before and after the use of oxytocin at
0.1 U/min. The Imax of the fibroid was expressed as a percentage compared with the Imax of the uterine wall.
16 Y. Wang et al.grayscale sonogram as a reference, the ROI of the fibroid
was manually set about 2 mm away from the margin of the
fibroid on the CEUS sonogram. The ROI of the uterine wall
was drawn in the same sonogram (Figure 1). The time-
intensity curve was obtained by software. The maximum
intensity (Imax) of the fibroid, the time-to-peak intensity
(TTP), and mean transit time (MTT) of both the fibroid and
the uterine wall were measured.
Differences in Imax, TTP, and MTT were evaluated with
Student t test. Statistical analyses were performed by using
Stata software (version 7.0; Stata Corporation, College
Station, TX, USA). Data were expressed as mean  standard
deviation. A p value < 0.05 was considered statistically
significant.
Results
After the administration of oxytocin, the wash-in of
microbubbles into the uterine wall was not slowed down on
CEUS and the Imax of the uterine wall did not change
significantly. However, the wash-in of microbubbles into
the fibroids was significantly slowed down. On CEUS, the
fibroids began to enhance from the periphery significantly
later after the use of oxytocin: only a few vessels could be
seen flowing slowly into the fibroids. The fibroids became
significantly darker on CEUS and they reached peak
enhancement much later after the use of oxytocin
(Figure 2). Software analyses indicated that the Imax of the
fibroids was significantly decreased by the use of oxytocin.
The baseline Imax of the fibroid was 102.7  59.5% (range,
13.8e242.3%), which decreased to 15.5  16.9% (range,
1.2e81.6%) after the use of oxytocin (p < 0.05). The TTP
and MTT of the fibroids were also significantly prolonged
after the use of oxytocin (p < 0.05). The baseline TTP and
MTTwere 15.9  4.8 seconds (range, 9.8e34.6 seconds) and
73.9  35.0 seconds (range, 29.7e175.7 seconds) respec-
tively, which were prolonged to 28.3  14.0 seconds (range,
10.5e85.7 seconds) and 119.4  109.2 seconds (range,SonoVue, wash-out of the microbubbles inside the fibroid is observe
observed inside the fibroid 18 seconds after bolus injection of Sono
wash into the fibroid 30 seconds after bolus injection of SonoVue. (
inside the fibroid 60 seconds after bolus injection of SonoVue. (G
uterine wall (yellow curve) before the use of oxytocin. The maximum
wall. (H) After the use of oxytocin, the maximum signal intensity of
the uterine wall. The time to peak and mean transit time were pr26.1e441.9 seconds), respectively after the use of oxytocin
(Table 1).
The heat rate, blood pressure, and oxygen saturation did
not change significantly after the administration of
oxytocin in all patients. Two patients felt tolerable mild
pain in the abdomen which disappeared soon after
discontinuation of oxytocin infusion. No severe adverse
effect was encountered during CEUS examinations.
Discussion
Minimizing the perfusion-mediated cooling effect is a
promising strategy to enhance the therapeutic efficacy for
HIFU ablation of uterine fibroids. A previous study showed
that targeted HIFU ablation of the feeding vessel of the
uterine fibroids could result in more efficient tumor ne-
crosis and the required thermal dose could be reduced
significantly [18]. However, target vessel ablation was
technically difficult as it required an exact three dimen-
sional overlay of angiography with intraoperative images.
Therefore, other methods need to be developed to reduce
the blood perfusion of the uterine fibroids during HIFU
ablation.
Oxytocin was proposed to be a potential drug for
decreasing the blood perfusion of uterine fibroids. In this
study, its effect on the blood perfusion of the fibroid was
observed by CEUS. After infusion of oxytocin, the Imax of
the fibroid was significantly decreased and the TTP and MTT
of the fibroid were significantly increased in all patients.
The Imax is representative of the vascular volume and
decreased Imax of the fibroid corresponded to fewer
vascular volume inside the fibroid. TTP and MTT are rep-
resentatives of the blood flow speed and increased TTP and
MTT of the fibroid corresponded to slower blood flow inside
the fibroid. These results suggested that the blood perfu-
sion of the fibroid was significantly reduced after the use of
oxytocin. Intravenous administration of oxytocin may
become a safe and effective method to reduce the bloodd, (D) After the use of oxytocin, no wash-in of microbubbles is
Vue. (E) After the use of oxytocin, the microbubbles began to
F) After the use of oxytocin, there is still minimal enhancement
) The time-intensity curves for the fibroid (green curve) and
signal intensity of the fibroid is higher than that of the uterine
the fibroid is significantly decreased, which is lower than that of
olonged after the administration of oxytocin.
Effects of Oxytocin on Fibroids: CEUS 17perfusion of the fibroids thereby enhancing the efficacy of
HIFU for ablation of uterine fibroids.
This study had some limitations. Firstly, the number of
enrolled patients was smalldthe effect of oxytocin should
be further tested in a larger cohort of patients. Secondly,
because the CEUS software was a trial version, some pa-
rameters like the area under the curve could not be
measured. Thirdly, only one dose was used in this study.
The appropriate therapeutic doses need to be further
investigated. Fourthly, to what extent oxytocin could
enhance the therapeutic effect of HIFU ablation is un-
known. We are undertaking randomized controlled trials to
answer this question.
In conclusion, our CEUS study showed that the blood
perfusion of uterine fibroids could be significantly reduced
by the administration of oxytocin. It may have clinical im-
plications for enhancing the efficacy of HIFU ablation for
the treatment of uterine fibroids.References
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